X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Holdings Boosted by Jane Street Group LLC

Jane Street Group LLC lifted its position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 103.4% in the 3rd quarter, Holdings Channel reports. The fund owned 248,447 shares of the company’s stock after buying an additional 126,296 shares during the period. Jane Street Group LLC’s holdings in X4 Pharmaceuticals were worth $166,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of XFOR. GSA Capital Partners LLP bought a new position in shares of X4 Pharmaceuticals during the third quarter worth about $340,000. K2 Principal Fund L.P. bought a new position in shares of X4 Pharmaceuticals during the second quarter worth about $284,000. AQR Capital Management LLC grew its position in shares of X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after acquiring an additional 388,115 shares during the last quarter. State Street Corp grew its position in shares of X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after acquiring an additional 189,105 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of X4 Pharmaceuticals by 39.7% during the second quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock worth $272,000 after acquiring an additional 133,398 shares during the last quarter. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $0.57 on Tuesday. The firm has a 50-day moving average price of $0.55 and a 200 day moving average price of $0.62. The firm has a market capitalization of $96.41 million, a PE ratio of -6.28 and a beta of 0.14. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals, Inc. has a 52-week low of $0.26 and a 52-week high of $1.60.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Stifel Nicolaus lowered their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright decreased their target price on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research report on Thursday, November 14th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.